Ratio of Aβ42/P-tau181p in CSF is associated with aberrant default mode network in AD

被引:0
|
作者
Xiaozhen Li
Tie-Qiang Li
Niels Andreasen
Maria Kristoffersen Wiberg
Eric Westman
Lars-Olof Wahlund
机构
[1] Care Sciences and Society,Department of Neurobiology
[2] Karolinska Institutet,Department of Medical Physics
[3] Karolinska Huddinge,Department of Clinical Science
[4] Karolinska Institutet,undefined
[5] Alzheimer Disease Research Center,undefined
[6] Karolinska Institutet,undefined
[7] Intervention and Technology,undefined
[8] Karolinska Institute,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The default mode network (DMN) is particularly relevant to Alzheimer's disease (AD) since its structures are vulnerable to deposition of amyloid. Decreased levels of β-amyloid1-42 (Aβ42) and increased total tau protein (T-tau) and tau phosphorylated at position threonine 181 (P-tau181p) in cerebrospinal fluid (CSF) have been established as valid biomarkers for the diagnosis and prognosis of AD. However, the relationship between CSF biomarkers and change in the DMN is still unknown. In this study we investigated the correlation between the functional connectivity within the DMN and the ratio of Aβ42/P-tau181p in the CSF. We found that the ratio of Aβ42/P-tau181p was moderately positively correlated with the functional connectivity within the DMN in the left precuneus/cuneus. This finding implicates that the brain functional connectivity within DMN is affected by pathological changes at early stage in AD. This may provide a better understanding of AD pathology progression and improve AD diagnosis.
引用
收藏
相关论文
共 50 条
  • [1] Ratio of Aβ42/P-tau181p in CSF is associated with aberrant default mode network in AD
    Li, Xiaozhen
    Li, Tie-Qiang
    Andreasen, Niels
    Wiberg, Maria Kristoffersen
    Westman, Eric
    Wahlund, Lars-Olof
    SCIENTIFIC REPORTS, 2013, 3
  • [2] Genome-wide association study of CSF biomarkers Aβ1-42, t-tau, and p-tau181p in the ADNI cohort
    Kim, S.
    Swaminathan, S.
    Shen, L.
    Risacher, S. L.
    Nho, K.
    Foroud, T.
    Shaw, L. M.
    Trojanowski, J. Q.
    Potkin, S. G.
    Huentelman, M. J.
    Craig, D. W.
    DeChairo, B. M.
    Aisen, P. S.
    Petersen, R. C.
    Weiner, M. W.
    Saykin, A. J.
    NEUROLOGY, 2011, 76 (01) : 69 - 79
  • [3] Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau181P
    Koopman, Karen
    Le Bastard, Nathalie
    Martin, Jean Jacques
    Nagels, Guy
    De Deyn, Peter P.
    Engelborghs, Sebastiaan
    NEUROCHEMISTRY INTERNATIONAL, 2009, 55 (04) : 214 - 218
  • [4] A single center study: Aβ42/p-Tau181 CSF ratio to discriminate AD from FTD in clinical setting
    Andrea Vergallo
    Cecilia Carlesi
    Cristina Pagni
    Filippo Sean Giorgi
    Filippo Baldacci
    Lucia Petrozzi
    Roberto Ceravolo
    Gloria Tognoni
    Gabriele Siciliano
    Ubaldo Bonuccelli
    Neurological Sciences, 2017, 38 : 1791 - 1797
  • [5] A single center study: Aβ42/p-Tau181 CSF ratio to discriminate AD from FTD in clinical setting
    Vergallo, Andrea
    Carlesi, Cecilia
    Pagni, Cristina
    Giorgi, Filippo Sean
    Baldacci, Filippo
    Petrozzi, Lucia
    Ceravolo, Roberto
    Tognoni, Gloria
    Siciliano, Gabriele
    Bonuccelli, Ubaldo
    NEUROLOGICAL SCIENCES, 2017, 38 (10) : 1791 - 1797
  • [6] Plasma p-tau181/Aβ1-42 ratio predicts Aβ-PET status and correlates with CSF-p-tau181/Aβ1-42 and future cognitive decline
    Fowler, Christopher J.
    Stoops, Erik
    Rainey-Smith, Stephanie R.
    Vanmechelen, Eugeen
    Vanbrabant, Jeroen
    Dewit, Nele
    Mauroo, Kimberley
    Maruff, Paul
    Rowe, Christopher C.
    Fripp, Jurgen
    Li, Qiao-Xin
    Bourgeat, Pierrick
    Collins, Steven J.
    Martins, Ralph N.
    Masters, Colin L.
    Doecke, James D.
    ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING, 2022, 14 (01)
  • [7] Cerebrospinal fluid P-tau181P: biomarker for improved differential dementia diagnosis
    Struyfs, Hanne
    Niemantsverdriet, Ellis
    Goossens, Joery
    Fransen, Erik
    Martin, Jean-Jacques
    De Deyn, Peter P.
    Engelborghs, Sebastiaan
    FRONTIERS IN NEUROLOGY, 2015, 6
  • [8] sTREM2 in discordant CSF Aβ42 and p-tau181
    Li, Danni
    Mantyh, William G.
    Men, Lu
    Jain, Ishika
    Glittenberg, Matthew
    An, Binchong
    Zhang, Lin
    Li, Ling
    Alzheimers Dis Neuroimaging Initiative
    ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING, 2025, 17 (01)
  • [9] Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia
    Borroni, Barbara
    Benussi, Alberto
    Archetti, Silvana
    Galimberti, Daniela
    Parnetti, Lucilla
    Nacmias, Benedetta
    Sorbi, Sandro
    Scarpini, Elio
    Padovani, Alessandro
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2015, 16 (1-2) : 86 - 91
  • [10] CSF p-Tau181/Tau ratio as biomarker for TDP pathology in Frontotemporal Dementia
    Benussi, A.
    Archetti, S.
    Galimberti, D.
    Parnetti, L.
    Nacmias, B.
    Ferrari, F.
    Sorbi, S.
    Scarpini, E.
    Padovani, A.
    Borroni, B.
    JOURNAL OF ALZHEIMERS DISEASE, 2014, 41 : S4 - S5